Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT03587948
Recruiting Observational

Shanghai Children and Adolescent Diabetes Eye Study

NCT03587948 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Phase
Observational
Started
2018-01-01
Last updated
2018-07-16

Condition(s) studied

Diabetes MellitusEye Diseases

Investigational drug(s) / intervention(s)

Diabetes mellitus

Diabetes mellitus: Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.

Study summary

To compare the prevalence of eye disease between children and adolescents with diabetes mellitus and healthy people, and to analyze the related factors of eye diseases in diabetic patients.

Eligibility

Sex
ALL
Min age
5 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * (1) provision of a written informed consent by a guardian; * (2) age over 5 years and less than 18 years; * (3) diagnosis of type 1 or type 2 diabetes based on the WHO diagnostic criteria for cases. Exclusion Criteria: * (1) eyelid diseases - eyelid entropion, eyelid ectropion, eyelid, ptosis, and palpebral dyskinesia; * (2) conjunctival diseases - pterygium and conjunctivitis; * (3) history of ocular surface chemical injury or use of eye drops with moisturizing artificial tears; * (4) history of eye surgery within 6 months or history of retinal laser photocoagulation; * (5) systemic diseases - Sjogren syndrome, Parkinson's disease, rheumatoid arthritis, Grave 's disease, systemic lupus erythematosus, and others.

Primary outcome measure(s)

  • Diabetic eye diseases — January 1, 2028
    Prevalence of eye diseases due to diabetes.

Trial sites (1)

FacilityCityRegionStatus
Shanghai Eye Disease Prevention & Treatment Center Shanghai Shanghai Municipality Recruiting

More Shanghai Eye Disease Prevention and Treatment Center trials in China

School-based Myopia Control Trial for Children With Premyopia or Myopia Recruiting
Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses Enrolling by invitation
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control Active, not recruiting
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia Recruiting
China Children Eye Study Recruiting

Other trials for the same condition

Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation Starting soon
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function Recruiting
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus Recruiting
New Triple Therapy in Newly Diagnosed Type 2 Diabetes Starting soon
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03587948 on ClinicalTrials.gov ↗ ← All trials in China